ICH GCP / Clinical Trials Registry · Jan 2026
Clinical-trial registry entry describing a study of the Q-Pad hrHPV test system for cervical screening and precancer detection using at-home menstrual samples.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Qvin (Qurasense, Inc.) is a Menlo Park-based women’s-health biotechnology company that developed the Q-Pad, an FDA-cleared diagnostic menstrual pad and at-home test kit that turns menstrual blood into lab reports for non-invasive health monitoring.
Primary product
Q-Pad diagnostic menstrual pad / at-home A1c test kit
Founded
2014
Headquarters
Menlo Park, California, United States
Team size
10-20
Industry
Biotechnology Research
Sub-industry
Women’s health diagnostics / femtech
Offices
0 jobs at Qvin
Check back later for new openings
Business model
Stage
Series A
Total raised
$12.4M
Latest round
Convertible Note · Apr 2024
Apr 2024 · StartX Accelerator
Oct 2020 · Y Combinator Continuity Fund
Sep 2019
Jul 2018 · Y Combinator
Leadership
Co-Founder & CEO
COO & Co-Founder
Co-CEO
VP of Research and Development
Head of Lab
Investors
Mission-driven and hard-working, with a relaxed office atmosphere, autonomy, and a stated emphasis on work-life balance; the team also signals willingness to push hard when needed.
Compensation
Public job material signals a compensation package plus equity, with medical and dental coverage (including dependents up to 80%) and generous vacation and parental leave; no public salary bands were found.
Benefits
Pricing
Direct-to-consumer test-kit sales centered on the Q-Pad A1c kit; public coverage shows the kit sold online, with no public insurance coverage signal.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
3K
ICH GCP / Clinical Trials Registry · Jan 2026
Clinical-trial registry entry describing a study of the Q-Pad hrHPV test system for cervical screening and precancer detection using at-home menstrual samples.
The Guardian · Oct 2025
Long-form feature discussing Qvin as one of the leading startups pursuing menstrual-blood diagnostics for women’s health.
Femtech Insider · Jan 2024
Coverage of Qvin’s FDA clearance, the CLIA-lab workflow, and the company’s broader biomarker ambitions in women’s health.
WWD · Jan 2024
Consumer-facing coverage noting the Q-Pad A1c kit’s public launch and reported $49 price point.
PR Newswire · Jan 2024
Press release announcing FDA clearance of the Q-Pad and A1c test, enabling at-home menstrual-blood-based A1c monitoring and broader biomarker testing.